Source comparison
BPC-157 + LL-37 Synergy: Mechanism Comparison
Primary Pathway VEGFR2 upregulation → angiogenesis via PI3K/Akt signalling FPRL1 activation → neutrophil chemotaxis and cytokine modulation via NF-κB BPC-157 establishes vascular scaffolding before LL-37 recruits immune cells LL-37's immune effects depend on v
This comparison does not assign a generated winner or score.
- Primary Pathway
- VEGFR2 upregulation → angiogenesis via PI3K/Akt signalling
- FPRL1 activation → neutrophil chemotaxis and cytokine modulation via NF-κB
- BPC-157 establishes vascular scaffolding before LL-37 recruits immune cells
- LL-37's immune effects depend on vascular access. Inject too early and cells can't reach the target
- Peak Effect Window
- 90–240 minutes post-injection (blood flow increase)
- 20–90 minutes post-injection (immune cell migration)
- 60–90 minute gap allows BPC-157's vascular changes to manifest before LL-37 peaks
- Simultaneous injection wastes LL-37's chemotactic window in under-vascularised tissue
- Receptor Saturation
- VEGFR2 density limits benefit above 500mcg
- FPRL1 activation plateaus at 400mcg; higher doses trigger inflammation
- Sequential dosing prevents HSPG binding competition at injection site
- Co-injection at high doses (>500mcg each) causes peptides to compete for subcutaneous diffusion
- Tissue Penetration
- Systemic after 2–4 hours; local effect sustained 6–8 hours
- Rapid diffusion; systemic clearance by 3 hours
- BPC-157's prolonged local effect allows LL-37 to act within an optimised environment
- LL-37 clears before BPC-157's angiogenic peak if dosed simultaneously. Losing the compounding window
- Evidence Base
- Croatian Institute study: 3.2× VEGFR2 mRNA at 4 hours
- Lund University: 35% faster wound closure in diabetic models
- Combined rat tendon study: 62% strength gain with 90-min interval vs 28% co-injection
- The 90-minute interval isn't a guideline. It's the difference between synergy and interference